The Annual General Meeting of Kancera AB

The Annual General Meeting of Kancera AB was held in Stockholm on 26 May, 2011.

Annual Report and discharge from liability
The Company’s Income Statement and Balance Sheet were adopted and the Board of Directors and the Chief Executive Officer were discharged from liability for the shortened financial year 28 April – 31 December, 2010.

Election of Board of Directors and Chairman of the Board and compensation to the Board
Håkan Mellstedt, Bernt Magnusson, Anders Essen-Möller, Thomas Olin and Erik Nerpin were re-elected as members of the Board. Anders Åberg had declined re-election.
Erik Nerpin was re-elected as Chairman of the Board.
The Meeting resolved that directors’ fees of in total SEK 250,000 shall be payable.

Authorization to issue new shares, warrants and convertible debentures
The Meeting resolved to authorize the Board to resolve, at one or more occasions prior to the next Annual General Meeting, to issue new shares with payment in cash, in kind or by set-off and to...

Kancera AB

About Kancera AB (publ)
Kancera is engaged in drug development that takes its start in new treatment concepts and ends with a drug candidate. Kancera is currently developing medicines for the treatment of leukemia and med...

View more


  CONTACT  
  • Dr. Thomas Olin
  • CEO
  • +46 73 520 40 01

Media